The chemokine superfamily revisited
10.1016/j.immuni.2012.05.008 · doi-reference
Exploring the stereochemistry of CXCR4-Peptide recognition and inhibiting HIV-1 entry with d-Peptides derived from chemokines
10.1074/jbc.m202063200 · doi-reference
A novel peptide antagonist of CXCR4 derived from the N-Terminus of viral chemokine vMIP-II
10.1021/bi992750v · doi-reference
CXCR4 mediated recognition of HIV envelope spike and inhibition by CXCL12
10.1038/s41467-025-63815-2 · doi-reference
68Ga/161Tb-Labeled CXCR4-Targeted probe with enhanced positive charge: improved affinity and longer tumor retention without survival benefit in mice models
10.1021/acs.jmedchem.5c03763 · doi-reference
CXCR4-Targeted radiopharmaceuticals for the imaging and therapy of malignant tumors
10.3390/molecules28124707 · doi-reference
The CXCR4-targeted theranostics era: a comprehensive review of a decade of progress (2015–2025)
10.7150/thno.130266 · doi-reference
A synthetic bivalent ligand of CXCR4 inhibits HIV infection
10.1016/j.bbrc.2013.05.038 · doi-reference
Structures of the CXCR4 chemokine receptor in complex with small molecule and cyclic peptide antagonists
10.1126/science.1194396 · doi-reference
Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging
10.7150/thno.11251 · doi-reference
Positron emission tomography imaging of tumors expressing the human chemokine receptor CXCR4 in mice with the use of 64Cu-AMD3100
10.1007/s11307-010-0466-y · doi-reference
Design, preclinical evaluation, and clinical translation of [68Ga]Ga/[177Lu]Lu-JH120061, A novel radiopharmaceutical targeting CXCR4
10.1158/1078-0432.ccr-26-0292 · doi-reference
Synthesis and evaluation of novel C-X-C chemokine receptor 4-Targeted radiotracers for oncological imaging
10.1021/acs.jmedchem.5c00735 · doi-reference
Discovery of tetrahydroisoquinoline-based CXCR4 antagonists
10.1021/ml400183q · doi-reference
Novel peptide-based PET probe for non-invasive imaging of C-X-C chemokine receptor type 4 (CXCR4) in tumors
10.1021/acs.jmedchem.1c00066 · doi-reference
Distinct functional sites for human immunodeficiency virus type 1 and stromal cell-derived factor 1α on CXCR4 transmembrane helical domains
10.1128/jvi.79.20.12667-12673.2005 · doi-reference
Exploratory studies on development of the chemokine receptor CXCR4 antagonists toward downsizing
10.4137/pmc.s422 · doi-reference
C-terminal–modified LY2510924: a versatile scaffold for targeting C-X-C chemokine receptor type 4
10.1038/s41598-019-51754-0 · doi-reference
Radiosynthesis and preclinical evaluation of a 68Ga-labeled tetrahydroisoquinoline-based ligand for PET imaging of C-X-C chemokine receptor type 4 in an animal model of glioblastoma
10.1186/s41181-024-00290-y · doi-reference
Selective PET imaging of CXCR4 using the Al18F-labeled antagonist LY2510924
10.1007/s00259-024-07025-w · doi-reference
Second generation Al18F-labeled D-amino acid peptide for CXCR4 targeted molecular imaging
10.1016/j.nucmedbio.2024.108906 · doi-reference
CXCR4 regulates growth of both primary and metastatic breast cancer
10.1158/0008-5472.can-04-1844 · doi-reference
Discovery of novel small molecule orally bioavailable C−X−C chemokine receptor 4 antagonists that are potent inhibitors of T-Tropic (X4) HIV-1 replication
10.1021/jm100073m · doi-reference
Radiopharmaceutical therapy in cancer: clinical advances and challenges
10.1038/s41573-020-0073-9 · doi-reference
Validation of [125I]CPCR4.3 as an investigative tool for the sensitive and specific detection of hCXCR4 and mCXCR4 expression in vitro and in vivo
10.1186/s13550-019-0545-2 · doi-reference
[177Lu]pentixather: comprehensive preclinical characterization of a first CXCR4-directed endoradiotherapeutic agent
10.7150/thno.19119 · doi-reference
Structural insights into CXCR4 modulation and oligomerization
10.1038/s41594-024-01397-1 · doi-reference
Structural mechanisms underlying the modulation of CXCR4 by diverse small-molecule antagonists
10.1073/pnas.2425795122 · doi-reference
A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors
10.1073/pnas.2235846100 · doi-reference
In vivo validation of 68Ga-labeled AMD3100 conjugates for PET imaging of CXCR4
10.1016/j.nucmedbio.2023.108335 · doi-reference
Crystal structure of the chemokine receptor CXCR4 in complex with a viral chemokine
10.1126/science.1261064 · doi-reference
AMD3100: a versatile platform for CXCR4 Targeting68 Ga-based radiopharmaceuticals
10.1021/acs.bioconjchem.5b00689 · doi-reference
[64Cu]NOTA-pentixather enables high resolution PET imaging of CXCR4 expression in a preclinical lymphoma model
10.1186/s41181-016-0020-6 · doi-reference
The influence of different metal-chelate conjugates of pentixafor on the CXCR4 affinity
10.1186/s13550-016-0193-8 · doi-reference
Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases
10.1371/journal.pone.0074548 · doi-reference
Preclinical evaluation of [64Cu]NOTA-CP01 as a PET imaging agent for metastatic esophageal squamous cell carcinoma
10.1021/acs.molpharmaceut.1c00600 · doi-reference
Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models
10.1158/1535-7163.mct-14-0850 · doi-reference
A benzenesulfonamide derivative as a novel PET radioligand for CXCR4
10.1016/j.bmc.2019.115240 · doi-reference
A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency
10.7150/thno.45537 · doi-reference
Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [64Cu]AMD3100 positron emission tomography
10.1158/0008-5472.can-09-4396 · doi-reference
